P1-392: DRUG DEVELOPMENT FOR AGITATION AND AGGRESSION IN ALZHEIMER'S DISEASE (AD): STUDY DESIGN AND OUTCOME MEASURES IN PHASE 2 STUDY OF SCYLLO-INOSITOL (ELND005 STUDY AG201)

2014 ◽  
Vol 10 ◽  
pp. P458-P458 ◽  
Author(s):  
Susan R. Abushakra ◽  
Patrick Kesslak ◽  
Matthias Kurth ◽  
Frank Fan ◽  
Menghis Bairu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Drug Development ◽  
Outcome Measures ◽  
Study Design ◽  
Phase 2 ◽  
Phase 2 Study

scholarly journals ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Nature Aging ◽  
2021 ◽  
Vol 1 (6) ◽  
pp. 521-534
Author(s):  
Petr Novak ◽  
Branislav Kovacech ◽  
Stanislav Katina ◽  
Reinhold Schmidt ◽  
Philip Scheltens ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Active Immunotherapy ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Randomized Phase 2

The Effects of ELND005 (Scyllo-Inositol) on Emergence of Neuropsychiatric Symptoms (NPS) in Mild/Moderate Alzheimer's Disease: Results from a 78-Week Phase 2 Study (P04.215)

Neurology ◽  
2012 ◽  
Vol 78 (Meeting Abstracts 1) ◽  
pp. P04.215-P04.215 ◽  
Author(s):  
P. Tariot ◽  
C. Lyketsos ◽  
G. Crans ◽  
J. Cedarbaum ◽  
C. Hernandez ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Neuropsychiatric Symptoms ◽  
Phase 2 ◽  
Phase 2 Study
Sign in / Sign up

Export Citation Format

Share Document